Fortem Financial Group LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Fortem Financial Group LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 247.6% during the 3rd quarter, Holdings Channel reports. The firm owned 17,468 shares of the company’s stock after purchasing an additional 12,443 shares during the period. Johnson & Johnson makes up approximately 1.9% of Fortem Financial Group LLC’s portfolio, making the stock its 10th biggest position. Fortem Financial Group LLC’s holdings in Johnson & Johnson were worth $2,601,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lake Point Wealth Management boosted its stake in shares of Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after purchasing an additional 169 shares during the last quarter. Islay Capital Management LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $42,000. FAI Wealth Management boosted its stake in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC raised its position in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the period. Finally, Crewe Advisors LLC raised its position in shares of Johnson & Johnson by 909.1% in the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after acquiring an additional 300 shares during the period. 67.44% of the stock is currently owned by institutional investors.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.

Shares of JNJ stock opened at $148.10 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The company has a market capitalization of $389.92 billion, a P/E ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The company’s 50 day moving average price is $148.57 and its two-hundred day moving average price is $146.59. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. During the same period last year, the company earned $2.12 earnings per share. The firm’s revenue was up 1.7% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 8 earnings per share for the current year.

A number of analysts recently weighed in on the stock. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Citigroup increased their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $164.93.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: How liquidity affects the bid-ask spread

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.